会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • N-phenyl amidines
    • N-苯基脒
    • US3928379A
    • 1975-12-23
    • US46675374
    • 1974-05-03
    • MEAD JOHNSON & CO
    • WU YAO HUALOBECK WALTER G
    • C07C65/24C07D207/08
    • C07C65/24Y10S514/826
    • N-Phenyl amidines which have diuretic, antithrombogenic, smooth muscle relaxant, anti-inflammatory and antiarrhythmic properties have been discovered. They are prepared by reacting a substituted aniline with a carboxamide selected from the group consisting of amides and lactams in the presence of phosphorus oxychloride. Typical examples of substituted N-phenyl amidines thus obtained are 5-methyl-2-(N-phenylbenzylamino)-1-pyrroline, 2-(Nphenylbenzylamino)-1-pyrroline, 3-((N-1-pyrrolin-2-yl-panisidino)methyl)indole and 4,5,6,7,8,9-hexahydro-2-(Nphenylphenethylamino)-3H-azonine. Indole substituted N-phenyl amidines can be rearranged to provide iminopyrrolidinylindoles which are useful as diuretic, antithrombogenic and smooth muscle relaxant agents. In the case of 3-((N-1-pyrrolin-2-yl-panisidino)methyl)indole, the rearranged product is 3-((2-(pmethoxyphenylimino)-1-pyrrolindinyl)methyl)indole.
    • 已经发现具有利尿,抗血栓形成,平滑肌松弛剂,抗炎和抗心律失常性质的N-苯基脒。 它们通过在磷酰氯存在下使取代的苯胺与选自酰胺和内酰胺的羧酰胺反应来制备。 由此获得的取代的N-苯基脒的典型实例是5-甲基-2-(N-苯基苄基氨基)-1-吡咯啉,2-(N-苯基苄基氨基)-1-吡咯啉,3 - [(N-1-吡咯啉-2 - 对 - 茴香酰基)甲基]吲哚和4,5,6,7,8,9-六氢-2-(N-苯基苯乙基氨基)-3H-吖嗪。 吲哚取代的N-苯基脒可以重排,以提供可用作利尿剂,抗血栓形成剂和平滑肌松弛剂的亚氨基吡咯烷基吲哚。 在3 - [(N-1-吡咯啉-2-基 - 对茴香酰基)甲基]吲哚的情况下,重排产物是3 - [[2-(对甲氧基苯基亚氨基)-1-吡咯烷基]甲基]吲哚。
    • 5. 发明授权
    • Phenylimidazolines for producing a neuronal blocking and antihypertensive effect
    • 用于产生神经元阻滞和抗高血压作用的苯基咪唑啉
    • US3898342A
    • 1975-08-05
    • US47771874
    • 1974-06-10
    • MEAD JOHNSON & CO
    • MATIER WILLIAM LESLEYCOMER WILLIAM TIMMEY
    • A61K27/00
    • The novel compounds of this invention are of the imidazoline class of heterocycles having substituents in the 2 and 4 imidazoline ring positions and optionally in the 3-position. Substituents in the 2-position include amino, hydroxyamino, alkylamino, benzylamino, halobenzylamino, dihalobenzylamino, allylamino, cycloalkylamino, hydrazino, and alkylidenehydrazino. Optional 3-position substituents are alkyl and benzyl. The substituent in the 4-position is comprised of phenyl or R-phenyl in which the R-substituent is selected from halogen, alkyl, benzyloxy, alkoxy, dialkoxy, 3-hydroxy, 3,4-dihydroxy, trifluoromethyl, phenyl, halophenyl, or alkylphenyl. The novel imidazolines have antihypertensive and neuronal blocking properties. They are prepared by cyclization of appropriately substituted 1-phenylethylenediamines with cyanogen bromide or by displacement of a methylmercapto grouping from an appropriately substituted 2-methylthioimidazoline. Representative embodiments of this invention are 2-amino-4-(4-chlorophenyl)-2-imidazoline and 2-amino-4-(3,4-dichlorophenyl)-2-imidazoline.
    • 本发明的新化合物是在2和4咪唑啉环位置以及任选在3-位具有取代基的咪唑啉类杂环。 2-位的取代基包括氨基,羟基氨基,烷基氨基,苄基氨基,卤代苄基氨基,二卤苄基氨基,烯丙基氨基,环烷基氨基,肼基和亚烷基肼。 任选的3-位取代基是烷基和苄基。 4-取代基由苯基或R-苯基组成,其中R取代基选自卤素,烷基,苄氧基,烷氧基,二烷氧基,3-羟基,3,4-二羟基,三氟甲基,苯基,卤代苯基, 或烷基苯基。 新型咪唑啉具有抗高血压和神经元阻断性能。 它们通过用溴化氰环化适当取代的1-苯基乙二胺或通过从适当取代的2-甲硫基咪唑啉置换甲基巯基来制备。 本发明的代表性实施方案是2-氨基-4-(4-氯苯基)-2-咪唑啉和2-氨基-4-(3,4-二氯苯基)-2-咪唑啉。
    • 6. 发明授权
    • Ocular hypotensive process employing dextrorotatory phenethanolamines
    • 使用右旋苯乙醇胺的眼压降过程
    • US3885047A
    • 1975-05-20
    • US42727473
    • 1973-12-21
    • MEAD JOHNSON & CO
    • SEIDEHAMEL RICHARD JDUNGAN KENDRICK W
    • A61K9/00A61K31/135A61K31/18A61K27/00
    • A61K31/135A61K9/0048A61K31/18
    • Dextrorotatory stereoisomers of beta-adrenergic stimulatory phenethanolamines such as isoproterenol, soterenol, salbutamol, carbuterol, terbutaline, and metaproterenol lower normal or elevated intraocular pressure when topically administered to the eye. Reduction in intraocular pressure is of particular importance in the treatment of glaucoma, a disease marked by ocular hypertension. The dextrorotatory phenethanolamine compounds employed in the process of the present invention are notable for the low order of adrenergic activity in contrast to levorotatory and racemic stereoisomeric forms which are very potent beta-adrenergic stimulatory agents. Consequently, those side effects generally associated with adrenergic activation such as tachycardia, mydriasis, hypertension and hypotension are absent.
    • 当局部施用于眼睛时,β-肾上腺素能刺激性苯乙醇胺如异丙肾上腺素,异丙肾上腺素,沙丁胺醇,卡特罗特,特布他林和偏多伦他丁的右旋立体异构体降低正常或升高的眼内压。 降低眼内压在治疗青光眼中是特别重要的,青光眼是由高眼压症引起的疾病。 在本发明方法中使用的右旋苯乙醇胺化合物与非常有效的β-肾上腺素能刺激剂的左旋和外消旋立体异构形式相反,对于肾上腺素能活性的低阶是显着的。 因此,通常与肾上腺素能活化相关的副作用如心动过速,散瞳,高血压和低血压都不存在。